Fludarabine, cyclophosphamide and 2 Gy TBI with PT-Cy as a single platform for haplo and unrelated donor allo-SCT in older AML or MDS patients.

One uniform transplant platform works equally well across different donor types, simplifying logistics for older patients needing stem cell rescue.

Single reduced-intensity platform (Flu/Cy/2Gy TBI + PT-Cy) applied uniformly to haploidentical and unrelated donor allo-SCT in older AML/MDS patients achieves comparable outcomes between donor types, simplifying transplant logistics and potentially improving access for older patients lacking matched sibling donors.

What the study was

Study design

retrospective_cohort

Category

hematologic_malignancies

Maturity

clinical

Journal

Bone Marrow Transplantation

A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.